TOVX logo

TOVX
Theriva Biologics Inc

24,135
Mkt Cap
$6.46M
Volume
1.1M
52W High
$2.03
52W Low
$0.1651
PE Ratio
-0.03
TOVX Fundamentals
Price
$0.1913
Prev Close
$0.1946
Open
$0.1941
50D MA
$0.2607
Beta
0.82
Avg. Volume
2.41M
EPS (Annual)
-$19.03
P/B
0.29
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
News Placeholder
Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong
The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01, in combination with standard chemotherapy.
Stocktwits·8mo ago
News Placeholder
TOVX Stock Jumps 30% As New Patent, FDA Designation Boost Investor Sentiment
Theriva recently secured Rare Pediatric Drug Designation (RPDD) from the U.S. FDA for VCN-01, its experimental treatment for retinoblastoma, the most common type of eye cancer in children.
Stocktwits·1y ago
<
...
1
>

Latest TOVX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.